Institution
American Pharmacists Association
Other•Washington D.C., District of Columbia, United States•
About: American Pharmacists Association is a other organization based out in Washington D.C., District of Columbia, United States. It is known for research contribution in the topics: Pharmacist & Pharmacy. The organization has 2413 authors who have published 1969 publications receiving 30470 citations. The organization is also known as: APhA & American Pharmaceutical Association.
Topics: Pharmacist, Pharmacy, Population, Health care, Clinical pharmacy
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, the authors generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis and chronic urticaria and atopic dermatitis) in order to have a unified definition of severity, control and risk, usable in most situations.
Abstract: Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies.
78 citations
••
TL;DR: The combination of itraconazole and inhaled corticosteroids is increasingly being used to treat conditions such as allergic bronchopulmonary aspergillosis and Clinicians need to be aware of the potential for an interaction between such a combination.
Abstract: OBJECTIVE:To report a case of an interaction between inhaled corticosteroids and itraconazole causing iatrogenic Cushing's syndrome and provide a review of the relevant literature.CASE SUMMARY:A 70-year-old white woman on long-term treatment with high-dose inhaled corticosteroids for asthma was diagnosed as having Scedosporium apiospermum infection of the skin and subcutaneous tissues. As a result, she was treated with itraconazole for 2 months. She subsequently developed Cushing's syndrome due to a probable cytochrome P450–mediated interaction between itraconazole and budesonide. She also had secondary adrenal insufficiency requiring prolonged treatment with replacement hydrocortisone.DISCUSSION:Budesonide is a potent glucocorticoid that is metabolized in the liver by the CYP3A4 isoenzyme to inactive metabolites. Itraconazole is a potent cytochrome P450 inhibitor. It can inhibit the metabolism of oral or inhaled corticosteroids, producing cortisol excess leading to Cushing's syndrome and adrenal insuffic...
76 citations
••
TL;DR: The formal emergency department (ED) has its roots in the 1950s, when full-time emergency services were established in the United States.
Abstract: Emergency medicine (EM) is an ever-changing, rapidly evolving practice specialty. The formal emergency department (ED) has its roots in the 1950s, when full-time emergency services were established in the United States.[1][1] Since then, the rate of mortality from accidental and traumatic injuries
76 citations
••
TL;DR: A randomized, double-blind, placebo-controlled trial has been designed to compare the efficacy and safety of two different formulations of clobetasol, a very potent topical steroid, in the topical management of OLP and to evaluate which gives the longest remission from signs and symptoms.
Abstract: Oral lichen planus (OLP) is a chronic inflammatory disease that can be painful, mainly in the atrophic and erosive forms. Numerous drugs have been used with dissimilar results, but most treatments are empirical and do not have adequate control groups or correct study designs. However, to date, the most commonly employed and useful agents for the treatment of LP are topical corticosteroids. A randomized, double-blind, placebo-controlled trial has been designed to compare the efficacy and safety of two different formulations of clobetasol, a very potent topical steroid, in the topical management of OLP and to evaluate which gives the longest remission from signs and symptoms. Thirty-five consecutive patients were divided into two groups: the first received clobetasol propionate 0.025% and the second was given clobetasol propionate 0.05%. Both drugs were placed in 4% hydroxyethyl cellulose bioadhesive gel. Anti-mycotic prophylaxis was also added. After the end of therapy, patients received a 2-month follow-up. In all, 14 of the 15 clobetasol 0.025% patients (93%) and 13 of the 15 clobetasol 0.05% patients (87%), had symptoms improvement after 2 months of therapy (P = 0.001 in both groups). Also, 13 of the 15 clobetasol 0.025% patients (87%) and 11 of the 15 clobetasol 0.05% patients (73%) had clinical improvement after 2 months of therapy (P < 0.05 in both groups). No statistical differences were found in comparing the two different formulations. A larger concentration of the active molecules cannot further improve the therapeutic findings or optimize the obtained results in a significant manner.
75 citations
••
TL;DR: It was shown that the concentration range of this overlapping range of SDCs tended to broaden and shift to lower concentrations with increasing age, raising the possibility that patients >71 years show clinical evidence of digoxin toxicity despite having S DCs within the recommended therapeutic range.
Abstract: OBJECTIVE:To evaluate the relationship of the therapeutic serum digoxin concentration (SDC) range (0.5–2 ng/mL, as recommended in previous clinical studies) with the incidence of digoxin toxicity during digoxin maintenance therapy.METHODS:Subjects included all inpatients (n = 462) and outpatients (n = 437) receiving digoxin oral maintenance therapy for heart failure and/or atrial fibrillation with tachycardia at Kosei Hospital, Anjo, Japan. SDC and blood chemistry analysis were determined, and a 24-hour Holter electrocardiographic recording was performed when the SDC was at the presumed steady-state concentration.RESULTS:Analysis of clinical data showed that there was an overlapping (toxic and nontoxic) range of SDCs in which the incidence of digoxin toxicity was patient-dependent (1.4–2.9 ng/mL). No patient exhibited signs or symptoms of digoxin toxicity when the SDC was 3 ng/mL. Additionally, it was shown that the concentration range of...
74 citations
Authors
Showing all 2426 results
Name | H-index | Papers | Citations |
---|---|---|---|
David Taylor | 131 | 2469 | 93220 |
John Strang | 76 | 651 | 22873 |
Antoine C. G. Egberts | 67 | 279 | 13896 |
David M. Burger | 61 | 575 | 18170 |
Helmut Schmidt | 59 | 366 | 13775 |
Helene McNulty | 49 | 222 | 7184 |
Lutz Heide | 48 | 182 | 6627 |
Larry H. Danziger | 43 | 170 | 6546 |
Abu T.M. Serajuddin | 42 | 128 | 8165 |
Leslie Hendeles | 42 | 220 | 6364 |
Cynthia A. Jackevicius | 42 | 179 | 6826 |
Vincent Launay-Vacher | 41 | 220 | 5981 |
Ron A. A. Mathot | 36 | 76 | 3032 |
L. Lee Dupuis | 35 | 201 | 5106 |
George A. Kenna | 33 | 63 | 2528 |